ELEVATION ONCOLOGY INC (ELEV)
US28623U1016 - Common Stock
Taking everything into account, ELEV scores 2 out of 10 in our fundamental rating. ELEV was compared to 568 industry peers in the Biotechnology industry. ELEV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ELEV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ELEV had negative earnings in the past year.
ELEV had a negative operating cash flow in the past year.
In the past 5 years ELEV always reported negative net income.
ELEV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -39.46%, ELEV perfoms like the industry average, outperforming 58.41% of the companies in the same industry.
ELEV's Return On Equity of -60.48% is fine compared to the rest of the industry. ELEV outperforms 60.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.46% | ||
| ROE | -60.48% | ||
| ROIC | N/A |
ROA(3y)-57.89%
ROA(5y)-100.9%
ROE(3y)-100.07%
ROE(5y)-155.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ELEV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ELEV has more shares outstanding than it did 1 year ago.
ELEV has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.61, we must say that ELEV is in the distress zone and has some risk of bankruptcy.
ELEV's Altman-Z score of -2.61 is in line compared to the rest of the industry. ELEV outperforms 50.62% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that ELEV is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.45, ELEV is doing worse than 72.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.61 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 17.77 indicates that ELEV has no problem at all paying its short term obligations.
The Current ratio of ELEV (17.77) is better than 93.27% of its industry peers.
ELEV has a Quick Ratio of 17.77. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
ELEV's Quick ratio of 17.77 is amongst the best of the industry. ELEV outperforms 93.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.77 | ||
| Quick Ratio | 17.77 |
3. Growth
3.1 Past
ELEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.04%, which is quite impressive.
EPS 1Y (TTM)62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ELEV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.37% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.57%
EPS Next 2Y17.65%
EPS Next 3Y8.98%
EPS Next 5Y10.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ELEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELEV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.65%
EPS Next 3Y8.98%
5. Dividend
5.1 Amount
No dividends for ELEV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ELEVATION ONCOLOGY INC
NASDAQ:ELEV (12/20/2024, 8:06:57 PM)
After market: 0.608 +0.03 (+4.83%)0.58
-0.05 (-7.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.39%
Inst Owner Change-17.4%
Ins Owners0.25%
Ins Owner Change0.16%
Market Cap34.29M
Analysts86.15
Price Target7.14 (1131.03%)
Short Float %11.79%
Short Ratio8.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.33%
Min EPS beat(2)-8.46%
Max EPS beat(2)21.12%
EPS beat(4)2
Avg EPS beat(4)5.67%
Min EPS beat(4)-11.52%
Max EPS beat(4)21.54%
EPS beat(8)3
Avg EPS beat(8)1.39%
EPS beat(12)4
Avg EPS beat(12)-2.89%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-12.5%
EPS NQ rev (1m)-3.87%
EPS NQ rev (3m)4.9%
EPS NY rev (1m)-2.2%
EPS NY rev (3m)-4.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.49 | ||
| P/tB | 0.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.46% | ||
| ROE | -60.48% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-57.89%
ROA(5y)-100.9%
ROE(3y)-100.07%
ROE(5y)-155.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.77 | ||
| Quick Ratio | 17.77 | ||
| Altman-Z | -2.61 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)100%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12%
EPS Next Y42.57%
EPS Next 2Y17.65%
EPS Next 3Y8.98%
EPS Next 5Y10.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-103.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.91%
OCF growth 3YN/A
OCF growth 5YN/A